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Von Recklinghausen’s disease is a relatively common familial genetic disorder characterized by inactivating
mutations of the Neurofibromatosis-1 (NF1) gene that predisposes these patients to malignancies, including an
increased risk for juvenile myelomonocytic leukemia. However, NF1 mutations are not common in acute
myeloid leukemia (AML). Given that the RUNX1 transcription factor is the most common target for chromosomal translocations in acute leukemia, we asked if NF1 might be regulated by RUNX1. In reporter assays,
RUNX1 activated the NF1 promoter and cooperated with C/EBP␣ and ETS2 to activate the NF1 promoter over
80-fold. Moreover, the t(8;21) fusion protein RUNX1-MTG8 (R/M), which represses RUNX1-regulated genes,
actively repressed the NF1 promoter. R/M associated with the NF1 promoter in vivo and repressed endogenous
NF1 gene expression. In addition, similar to loss of NF1, R/M expression enhanced the sensitivity of primary
myeloid progenitor cells to granulocyte-macrophage colony-stimulating factor. Our results indicate that the
NF1 tumor suppressor gene is a direct transcriptional target of RUNX1 and the t(8;21) fusion protein,
suggesting that suppression of NF1 expression contributes to the molecular pathogenesis of AML.
cient to promote tumorigenesis (16). These effects are due in
part to the role of the NF1 gene product, neurofibromin, as a
negative regulator of RAS and other small GTP binding proteins, acting to accelerate GTP hydrolysis (5, 11, 25). Loss of
NF1 results in increased RAS-mediated signaling in response
to multiple stimuli, including granulocyte-macrophage colonystimulating factor (GM-CSF), leading to excessive proliferation and increased cell survival of lymphoid and myeloid progenitor cells (26, 35, 67).
RUNX1 (runt-related 1, also known as AML 1 or AML1) is
a DNA binding transcription factor that acts as a molecular
switch to activate or repress transcription. Although RUNX1
can associate with coactivators, it appears to activate transcription through composite sites in which the RUNX1 DNA binding site is adjacent to sites for factors that RUNX1 can physically associate with, such as C/EBP␣, PU.1, and ETS1, to form
an active transcriptional complex (22, 31, 54, 57, 64, 66). For
example, when expressed alone, RUNX1, C/EBP␣, and PU.1
are poor activators of the M-CSF promoter. However, when
coexpressed, RUNX1 synergizes with C/EBP␣ or PU.1 to potently activate transcription (54). Conversely, when expressed
in some cell types, RUNX1 is capable of repressing transcription through the recruitment of mSin3 and Groucho corepressors and histone deacetylases (HDACs) (13, 38, 46).
The function of RUNX1 is perhaps disrupted more than any
other transcription factor in acute leukemia. Chromosomal
translocations that affect RUNX1 include t(12;21), which is
present in 20 to 25% of pediatric acute B-cell lymphoblastic

Von Recklinghausen’s disease, or neurofibromatosis type I,
is a common inherited tumor predisposition syndrome with an
overall incidence of approximately 1 in 3,000 worldwide. Affected individuals are prone to the development of benign
tumors, such as neurofibromas, and malignant cancers, including glioma, malignant peripheral nerve sheath tumors, and
leukemia (28, 59). The disease is characterized by inactivating
mutations of the Neurofibromatosis-1 (NF1) gene (11, 17, 61),
which indicates that NF1 is a tumor suppressor gene. Patients
with mutant NF1 are at increased risk for clonal myeloproliferative diseases, including juvenile monomyelocytic leukemia
(JMML) (59, 60). In contrast, NF1 mutation has rarely been
detected in acute myeloid leukemia (AML) (29, 42, 55, 56).
Relatively small reductions in the expression of NF1 produce phenotypic changes in cell proliferation. For example,
Nf1⫹/⫺ astrocytes exhibit increased cell proliferation and motility (3). Similarly, loss of only one NF1 allele is sufficient to
partially complement defects in coat color and mast cells in
mice containing mutations in the c-Kit receptor tyrosine kinase
(W41 mice) that attenuate Ras-dependent signaling (26). In
addition, repression of NF1 by human immunodeficiency virus
Tax predisposes transgenic mice expressing Tax to neurofibromas, indicating that loss of NF1 expression by transcriptional
regulation, rather than NF1 mutational inactivation, is suffi* Corresponding author. Mailing address: Department of Biochemistry, Vanderbilt University School of Medicine, PRB 512, 23rd and
Pierce, Nashville, TN 37232. Phone: (615) 936-3582. Fax: (615) 9361790. E-mail: scott.hiebert@vanderbilt.edu.
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MATERIALS AND METHODS
Cell culture, reporter assays, and plasmids. HEL, Kasumi-1, HeLa, COS7-L
(Invitrogen), and GP2-293 cells were cultured as previously described (2, 39).
The NF1 promoter fragment was subcloned into pGL2-basic (Promega) and the
promoter deletions created by restriction digest and religation at the indicated
positions relative to the transcriptional start site (18). Expression plasmids for
RUNX1, C/EBP␣, ETS2, PU.1, and RUNX1-MTG8 and its mutants were described previously (6, 34, 39, 65). Transfection was performed in 6-well or 12-well
plates with 1 g of NF1-luciferase plasmid unless otherwise indicated using
Polyfect (QIAGEN). Firefly luciferase activity was measured using the Luciferase Assay kit (Promega) and corrected for transfection efficiency by including
plasmids expressing Renilla luciferase or secreted alkaline phosphatase (45).
ChIP. Chromatin immunoprecipitation (ChIP) was performed according to
the Upstate Biotechnologies ChIP assay protocol with Kasumi-1 or HeLa cells
and 4.0 g of each antibody (see Fig. 3 and Fig. 6). After immunoprecipitation
overnight at 4°C, DNA was purified by QIAquick PCR Purification kit (QIAGEN) and 5% of the purified products were used for PCR templates. Promoter
sequences were detected with the following PCR primers for NF1: a (forward,
⫺2313 to ⫺2291; reverse, ⫺2133 to ⫺2159), 5⬘-GGCCTGAAGTTTGGGTGT
CTTA-3⬘ and 5⬘-TGTAGGGAAGAAGATCAGGGAGATAG-3⬘; b (forward,
⫺1337 to ⫺1318; reverse, ⫺1181 to ⫺1202), 5⬘-GCACTCCACTGCACAGAG
TCA-3⬘ and 5⬘-CCCACCTCAGCCTCCCAAAGT-3⬘; p16INK4a, 5⬘-AGAAAGA
GGAGGGGCTGGCTGGTCA-3⬘ and 5⬘-CAGCCGTCAGCCGAAGGCTCC
A-3⬘. PCR was performed using HotStarTaq (QIAGEN) or a QuantiTect SYBR
Green PCR kit (QIAGEN) on an i-Cycler (Bio-Rad).
Retroviral infection of murine myeloid progenitor cells. To determine the fetal
genotype, once the liver was removed, the remainder of the embryonic tissue was
used for preparing genomic DNA as previously described (5). Primers were
employed to distinguish disrupted and wild-type alleles using PCR (28).

Recombinant retroviral plasmids were transfected into a GP⫹E 86 packaging
cell line as previously described (20). Stable populations of packaging cells
expressing the retrovirus were selected by serially separating green fluorescent
protein-positive (GFP⫹) cells by fluorescence-activated cell sorter (FACS) until
more than 95% of the cells were GFP⫹. The transduction protocol has been
previously described (19). Briefly, embryonic day 13.5 fetal liver cells were prestimulated for 48 h in liquid cultures of IMDM (Invitrogen Corporation, Grand
Island, NY) containing 20% fetal bovine serum (BioWhittaker, Walkersville,
MD) supplemented with 100 ng/ml stem cell factor (SCF; PeproTech, Rocky
Hill, NJ) and 200 U/ml IL-6 (PeproTech, Rocky Hill, NJ). Cells were subsequently transduced with viral supernatants on RetroNectin-treated non-tissue
culture plates (TaKaRa Bio, Inc., Madison, WI) for 48 h in the presence of SCF
and IL-6. Mast cell lines were then established from these transduced progenitors for immunoblot analysis (2).
For methylcellulose colony assays, transduced fetal liver cells were incubated
with1 g of phycoerythrin-conjugated c-Kit antibody/106 cells (PharMingen, San
Diego, CA) for 20 min at 4°C. Cells were then washed twice with 0.5% bovine
serum albumin in phosphate-buffered saline. GFP⫹ c-Kit⫹ cells were then separated by FACS. This enriched hematopoietic progenitor population of cells was
plated at a concentration of 5,000 cells/ml in triplicate methylcellulose cultures
(Stem Cell Tech, Inc., Vancouver, British Columbia, Canada) containing increasing concentrations of GM-CSF (0.01 to 2 ng/ml; PeproTech, Rocky Hill, NJ) or
IL-3 (0.1 to 10 U/ml; PeproTech, Rocky Hill, NJ), and granulocyte macrophage
CFU were scored on day 7 of culture.
Protein and RNA analysis. Viral supernatants were prepared using vesicular
stomatitis virus G glycoprotein-pseudotyped retrovirus from the GP2-293 packaging cell line (Clontech). Infected HeLa cells were selected in puromycin before
protein or RNA analysis. COS7-L cells were transfected using Lipofectamine
2000 (Invitrogen). Antibodies directed to human NF1 (10), human p14ARF
(Ab-1; Neomarkers), glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(ab8245-100; Norus Biologicals), the MTG8 zinc finger domain (␣-ETO/MTG8
ZnF Ab-1; CalBiochem/EMD Biosciences), and RUNX1 (␣-N-RUNX1 and
␣-RHD-RUNX1; CalBiochem/EMD Biosciences) were used for immunoblot
analysis. RNA was isolated using an RNeasy Mini kit (QIAGEN), and 10 g was
run on a 1% formaldehyde gel and probed with a radiolabeled NF1 cDNA
fragment encompassing exon 33, a 400-bp fragment of p14ARF encompassing
exon 1␤, or the full-length c-Myc and GAPDH cDNAs.
NF1 expression in primary AML samples. Total RNA was extracted from
bone marrow samples of 49 AML patients obtained at the time of initial diagnosis. Written consent was obtained from all patients. The presence or absence
of RUNX1-MTG8 was analyzed using standard reverse transcription (RT)-PCR
procedures and/or cytogenetics. Each sample was analyzed for NF1 or porphobilinogen deaminase gene (PBGD) expression two times by real-time quantitative RT-PCR (QRT-PCR) with specific primers and fluorescence-labeled probes
(TaqMan assay). To avoid amplification of homologous sequences and possible
NF1 pseudogenes, we used primers from exons 37 and 38, which are separated
by an intron of 3 kb to eliminate priming from genomic DNA (NF1 forward,
5⬘-GGACACTGCTCAATATCGCATTAC-3⬘; reverse, 5⬘-AGGTACAAGTTA
AGGCAC ACAGAAGA-3⬘; probe, 5⬘-FAM-GACCGTAAACTCGGGTCAG
AACTGCCTA-3⬘). To test whether the PCR would amplify DNA sequences, 0
to 50 ng of human genomic DNA was used as the template with no resulting
product. When analyzed by gel electrophoresis, the QRT-PCR product obtained
from patient samples was a single band of the expected size (96 bp). The RNA
isolation, cDNA synthesis and input, cycling conditions, and PBGD expression
measured for normalization were as described previously (39). From each sample, the quantity of NF1 and PBGD mRNAs was measured in duplicate using
serial dilutions of cell line RNA as a calibration curve. The PBGD mRNA
primers used were as follows: forward, 5⬘-GGCAATGCGGCTGCAA-3⬘; reverse, 5⬘-GGGTACCCACGCGAATCAC-3⬘. They were used in combination
with a VIC-labeled probe (5⬘-VIC-CATCTTTGGGCTGTTTTCTTCCGCC-3⬘).
Total RNA was isolated using RNAzol (Campro Scientific). For cDNA synthesis,
1 g total RNA was reverse transcribed using random hexanucleotide primers.
PCR was performed using universal mastermix (Applied Biosystems). Samples
were heated for 2 min at 50°C and 10 min at 95°C and amplified for 45 cycles of
15 s at 95°C and 60 s at 60°C on an ABI/Prism 7700 sequence detector (Applied
Biosystems).
Statistical analysis was performed using Minitab release 12 (Minitab, Inc.), and
P values and confidence intervals determined using the nonparametric MannWhitney rank sum test. For example, in comparing AML to AML-M2 samples,
for C1, n ⫽ 34 and median ⫽ 0.388 and for C2, n ⫽ 15 and median ⫽ 0.100; the
point estimate for ETA1-ETA2 is 0.204, the 95.0% confidence interval for ETA1
⫺ ETA2 is 0.073 to 0.365, W ⫽ 974.5, and the test of ETA1 ⫽ ETA2 versus
ETA1 not ⫽ ETA2 is significant (P ⫽ 0.0071; adjusted for ties).
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leukemias, and t(8;21), which is the most frequent chromosomal translocation associated with AML, accounting for 10 to
15% of the cases (58). In addition, inv(16), which may be the
second most frequent chromosomal abnormality in AML (58),
fuses the RUNX1-interacting factor, core binding factor ␤
(CBF␤), to a smooth-muscle myosin heavy-chain gene (40).
The inv(16) fusion protein dominantly inactivates RUNX1dependent transactivation and stimulates RUNX1-dependent
repression (1, 13, 30, 44). t(8;21) creates a fusion protein that
acts as a transcriptional repressor by fusing the N-terminal
DNA binding domain of RUNX1 to a putative transcriptional
corepressor known as MTG8 (myeloid translocation gene on
chromosome 8, also known as eight-twenty-one or ETO).
MTG8 contacts both the mSin3 and N-CoR families of corepressors, as well as HDAC1, HDAC2, and HDAC3 (2, 21).
Thus, repression of RUNX1-regulated genes may contribute
to leukemogenesis in over 20% of acute leukemias.
Given that the levels of expression of NF1 in AML may be
epigenetically altered or transcriptionally regulated, rather
than the locus mutated (41, 42), we asked whether the master
regulatory factors C/EBP␣ and RUNX1, which are mutated in
AML, might regulate NF1. We found multiple RUNX1, ETS,
and C/EBP␣ DNA binding sites, some of which were clustered
as in other genes regulated by these factors. RUNX1 and
C/EBP␣ independently activated the NF1 promoter and cooperated to dramatically activate NF1. By contrast, the t(8;21)
fusion protein, which disrupts RUNX1 and represses C/EBP␣
(52), repressed the NF1 promoter in reporter assays and repressed expression of the endogenous NF1 gene. Like inactivation of NF1 in individuals with neurofibromatosis, RUNX1MTG8 expression sensitized myeloid progenitor cells to
proliferation in response to GM-CSF, but not interleukin-3
(IL-3). These data suggest that repression of NF1 may contribute to t(8;21)-mediated leukemogenesis.
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RESULTS

transactivation. We mutated the proximal RUNX1 consensus
sequence CGTGGT at ⫺758 to CGCGAG (Fig. 1D, left side)
and tested the ability of RUNX1 and ETS2 to cooperatively
activate this promoter. Compared to the minimal promoter
(⫺59) that lacks all of the RUNX1 sites, RUNX1 and ETS2
once again cooperated to activate the ⫺969 promoter (Fig. 1D,
right side). Although RUNX1 still activated the mutant promoter, probably through a putative weak RUNX1 binding site
at ⫺661, only additive, not cooperative, effects were observed
when RUNX1 was coexpressed with ETS2 with the mutant
promoter (Fig. 1D, right side).
The t(8;21) fusion protein represses NF1 gene expression.
RUNX1-MTG8 (also known as AML1-ETO) represses genes
that contain RUNX1 binding sites (43). Therefore, we tested
whether RUNX1-MTG8 could also regulate the NF1 promoter in reporter assays (Fig. 2A and B). RUNX1-MTG8
repressed NF1 transcription, whereas a point mutant (L148D)
that fails to bind to DNA (37) or a C-terminal deletion mutant
(⌬469) that truncates the fusion protein prior to the oligomerization domain, and therefore lacks association motifs for
mSin3, N-CoR/SMRT, and HDACs (2, 37), failed to repress
the NF1 promoter (Fig. 2B). CBF␤ stimulates the DNA binding functions of the fusion protein, and as expected, the addition of this cofactor increased the ability of wild-type RUNX1MTG8, but not the mutants, to repress NF1 (Fig. 2B).
Based on our analysis of RUNX1-mediated transactivation,
we used a subset of our deletion mutants of the NF1 promoter
to determine the sequences required for RUNX1-MTG8-mediated repression. Deletion of the sequences from ⫺3363 to
⫺2732 had little effect on both the basal activity of the promoter and the ability of RUNX1-MTG8 to repress the promoter. Further deletion to ⫺1285 reduced the basal activity of
the promoter by 70%, but the ability of RUNX1-MTG8 to
repress the promoter remained until deletion to ⫺548 that
removes all of the consensus RUNX1 binding sites (Fig. 2C).
This result prompted us to test the ⫺969 promoter fragment
with and without the RUNX1 consensus binding site (Fig. 1D)
to determine whether this site is sufficient to mediate RUNX1MTG8-dependent repression. Although the level of repression
by the fusion protein was somewhat lower in this assay, mutation of the RUNX1 binding site impaired RUNX1-MTG8mediated repression (Fig. 2D).
RUNX1-MTG8 binds the NF1 promoter in vivo. Given the
results of the promoter analysis, we asked whether RUNX1MTG8 associates with NF1 in the context of native chromatin.
Kasumi-1 cells that contain t(8;21) were cross-linked with
formaldehyde, and the DNA associated with RUNX1-MTG8
was isolated using ChIP. The RUNX1-MTG8-associated chromatin was then interrogated for the presence of NF1 promoter
sequences using PCR. Primers flanking the clusters of RUNX1
binding sites labeled a and b in Fig. 3A were selected because
the shearing of genomic DNA to 200 to 800 bp in size allows
these primers to detect RUNX1-MTG8 bound to several of the
perfect and consensus RUNX1 binding sites. Using antibodies
directed to RUNX1, we were able to detect both the a and b
clusters of RUNX1 binding sites in NF1 associated with
RUNX1-MTG8 in Kasumi-1 cells (Fig. 3B, anti-N-RUNX1,
upper and middle parts). As a control, the NF1 promoter failed
to copurify with antibodies directed to RUNX2 and RUNX3,
which are not expressed at detectable levels in Kasumi-1 cells

Downloaded from http://mcb.asm.org/ on January 6, 2014 by Washington University in St. Louis

RUNX1, C/EBP␣, and ETS factors cooperate to regulate
NF1. Patients with NF1 mutations are at increased risk for the
formation of JMML (59, 60), but mutations in NF1 have not
been reported in sporadic AML, leaving open the possibility
that this tumor suppressor is regulated transcriptionally. Given
the high frequency of disruption of RUNX1 in acute leukemia,
we asked if RUNX1 regulates NF1. We identified 13 consensus
RUNX1 binding sites in the human NF1 promoter, with 7 of
these sites matching the narrower consensus sequence TGT/
cGGT (47) (Fig. 1A). Because RUNX1 cooperates with
C/EBP␣ and mutations in C/EBP␣ are associated with M2
AML (53), we also inspected the NF1 promoter for C/EBP␣
binding sites. Three of the C/EBP␣ binding sites were clustered near RUNX1 sites, similar to other genes that are coregulated by these factors (22, 31, 54, 57, 66). This raised the
possibility that NF1 is a transcriptional target of RUNX1 and
C/EBP␣. We confirmed that RUNX1 and C/EBP␣ bind these
sites in gel mobility shift assays (data not shown). In reporter
assays, RUNX1 activated the NF1 promoter and the level of
activation was enhanced by coexpression of the RUNX1 cofactor CBF␤, which increases RUNX1 DNA binding and stability (23, 24) (Fig. 1B and data not shown). In addition,
C/EBP␣ activated NF1 approximately sevenfold, but this activation was lost when higher levels of C/EBP␣-expressing plasmid were used (Fig. 1B and data not shown). When C/EBP␣
was coexpressed with RUNX1, these factors dramatically cooperated to activate the NF1 promoter over 80-fold (Fig. 1B).
ETS family members also cooperate with RUNX1 to activate transcription, and ETS factor sites are also adjacent to the
RUNX1 binding sites in the NF1 promoter (Fig. 1A). Therefore, we tested whether the NF1 promoter can be regulated by
RUNX1 and the ETS family members ETS2 and PU.1 in
reporter assays. Similarly, ETS2 or PU.1 only modestly activated the NF1 promoter. However, when RUNX1 was coexpressed with ETS2, these factors cooperated to activate the
NF1 promoter over 90-fold (Fig. 1B). Thus, RUNX1 cooperates with C/EBP␣ and ETS2 to regulate NF1.
The presence of multiple RUNX1, ETS, and C/EBP␣ binding sites in the NF1 promoter prompted us to attempt to
identify the RUNX1 binding sites that are required for regulation of NF1. Because of the large number of binding sites in
this promoter, we did not attempt to mutate each site individually but performed deletion analysis of the promoter (Fig.
1A). Deletion of the sequences from ⫺2732 to ⫺1285 reduced
the ability of these factors to cooperatively activate NF1 (Fig.
1C, left side). Further deletion to nucleotide ⫺969 dramatically impaired the cooperative activation, and deletion to
⫺548, which removes the last RUNX1 binding site, yielded
only additive, not cooperative, transactivation (Fig. 1C, right
side). Thus, the transcription factor binding sites clustered
between the AvrII and Tth111I sites are most clearly required
for the cooperative action of RUNX1, ETS2, and C/EBP␣,
although other sites such as the cluster of sites approximately
2.3 kbp upstream of the transcriptional start may also contribute to the regulation of NF1.
To demonstrate specificity for the cooperative regulation of
NF1, we used the ⫺969 promoter fragment that contains a lone
consensus RUNX1 binding site but retains some cooperative
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FIG. 1. RUNX1 cooperates with C/EBP␣ and ETS2 to regulate the NF1 promoter. (A) Schematic diagram of the NF1 promoter showing the
consensus RUNX1, C/EBP␣, and ETS factor binding sites relative to the transcriptional start site (arrow) along with the promoter deletions
analyzed in panels C and D. (B) RUNX1 cooperates with C/EBP␣ and ETS family members to activate NF1. HeLa cells were transfected with
0.4 g of the NF1-luciferase plasmid and increasing amounts of plasmids expressing RUNX1, C/EBP␣, PU.1, or ETS2 as indicated. pCMV5 was
added to keep the total amount of DNA constant, and the values were corrected to account for transfection variation by cotransfecting Rous
sarcoma virus-Renilla luciferase and adjusting the firefly luciferase values accordingly. Error bars demonstrate the standard deviation. (C) Analysis
of the promoter deletions depicted in panel A. Each promoter deletion was tested with RUNX1, ETS2, or C/EBP␣ alone or in combination
(R⫹E⫹C). Error bars demonstrate the standard deviation from an experiment performed in triplicate. (D) The synergistic transactivation of the
NF1 promoter by RUNX1 and ETS2 requires a RUNX1 binding site. The proximal RUNX1 consensus site at ⫺758, CGTGGT, was mutated to
CGCGAG as shown schematically at the left. The ⫺59 minimal promoter was used as a negative control. Each promoter was tested with RUNX1,
ETS2, or both (R⫹E). Error bars demonstrate the standard deviation. Shown in each part is a representative experiment out of several performed,
all of which yielded similar effects upon expression of the indicated proteins. CMV, cytomegalovirus.
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FIG. 2. RUNX1-MTG8 represses the NF1 promoter. (A) Schematic diagram of the NF1 promoter and the deletion mutants used in
panels C and D. The positions of the restriction sites used to create the
promoter fragments are shown relative to the transcriptional start site,
which is indicated by the arrow (⫹1). (B) RUNX1-MTG8-mediated
repression of the NF1 promoter requires DNA binding and corepressor binding domains. HeLa cells were transfected with the NF1-luciferase plasmid and increasing amounts of pCMV5-RUNX1-MTG8
(R/M) and pCMV5-RUNX1-MTG8(L148D), which cannot bind DNA,
or pCMV5-RUNX1-MTG8(⌬469), which removes multiple corepressor
binding domains (2), with or without pCMV5-CBF␤. pCMV5 was
added to keep the total amount of DNA constant, and the values were

corrected to account for transfection variation by cotransfecting Rous
sarcoma virus-Renilla luciferase or cytomegalovirus (CMV)-secreted
human placental alkaline phosphatase and adjusting the firefly luciferase values accordingly. Error bars demonstrate the standard deviation of independent analyses. (C) Analysis of the promoter deletions
depicted in panel A. HeLa cells were transfected with the indicated
NF1-luciferase plasmid (shown in panel A) with or without pCMV5RUNX1-MTG8. Error bars demonstrate the standard deviation from
an experiment performed in triplicate. (D) RUNX1-MTG8-mediated
repression of NF1 requires the presence of RUNX1 binding sites.
HeLa cells were transfected as described for panel B with the same set
of luciferase plasmids used in Fig. 1D with or without pCMV5-RUNX1MTG8. Error bars demonstrate the standard deviation. Shown is a
representative experiment out of several performed, all of which
yielded similar effects upon expression of the fusion protein. RLU,
relative light units.
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(data not shown), or antibodies directed to the yeast transcription factor GAL4 (Fig. 3B, upper part). Moreover, an antibody
directed to the DNA binding domain of RUNX1 (␣-RHD)
that does not recognize RUNX1 when bound to DNA also was
used as a negative control (Fig. 3B).
Because Kasumi-1 cells also express RUNX1, we used antiMTG8 in ChIP analysis to separate the fusion protein from
wild-type RUNX1. NF1 copurified with anti-MTG8 from Kasumi-1 cells, indicating that the fusion protein was associated
with NF1 in these cells (Fig. 3B). By contrast, the NF1 promoter was not detected using anti-MTG8 in HEL cells (Fig.
3C), which lack the fusion protein. QRT-PCR demonstrated at
least an eightfold (three-cycle) enhancement of NF1 promoter
sequences associated with anti-RUNX1 compared to control
antibodies and essentially no association with the p16ink4A promoter, which lacks RUNX1 binding sites (Fig. 3D).
To confirm that RUNX1 can also contact the NF1 promoter
in the absence of the background of the fusion protein, we
performed ChIP assays using HEL cells that express easily
detectable levels of RUNX1 but fail to express RUNX2 or
RUNX3. Only antibodies directed to RUNX1 copurified with
the NF1 promoter sequences (Fig. 3C). Thus, NF1 is bound by
both RUNX1 and RUNX1-MTG8.
RUNX1-MTG8 represses endogenous NF1 gene expression.
RUNX1-MTG8 can repress the NF1 promoter in reporter
assays (Fig. 2) and associates with the NF1 promoter on native
chromatin (Fig. 3). Therefore, we asked whether the fusion
protein represses endogenous NF1. Because we did not expect
complete silencing of NF1, a potential obstacle to measuring
repression of an endogenous gene is the stability of its mRNA
or protein. Therefore, we first determined the stability of NF1
protein (neurofibromin) and mRNA. HeLa or Cos7-L cells
were cultured in the presence of cycloheximide or actinomycin
D, and samples removed at various times after addition of the
drug for preparation of protein samples or RNA, respectively.
Immune and RNA blot analyses were used to determine the
half-lives (t1/2s) of NF1 protein and mRNA (Fig. 4A and B).
Compared to c-Myc, which has a short t1/2, the NF1 protein
and mRNA were long-lived, with a t1/2 of NF1 protein of over
10 h and a t1/2 of NF1 mRNA of nearly 8 h.
The stability of the NF1 mRNA and protein required that we
maintain expression of RUNX1-MTG8 for several days. Although counterintuitive, it is well established that the fusion
protein inhibits cell cycle progression and its expression is
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difficult to maintain for extended periods of time (2, 8). Therefore, we used retroviral infection of HeLa cells, a cell type that
allows RUNX1-MTG8 expression for several days with minimal effects on the cell cycle (39), to express RUNX1-MTG8.
Three days after infection, RUNX1-MTG8-expressing cells
had reduced levels of NF1 mRNA (Fig. 4C). The level of NF1
protein was reduced at 5 and 8 days after RUNX1-MTG8
expression, subsequent to the reduction of NF1 mRNA (Fig.
4C and 4D). As a negative control, the levels of GAPDH were
unaffected, whereas the levels of a known direct target of
RUNX1-MTG8, p14ARF (39), were also repressed (Fig. 4C and
D). To confirm the RUNX1-MTG8-mediated repression of
NF1 in a second cell type, we transfected COS7-L cells, which
were selected based on their high transfection efficiency. Using
a RUNX1-MTG8-IRES-GFP-expressing plasmid, we confirmed that greater than 95% of the cells expressed GFP as
measured by FACS analysis 3 to 5 days after transfection (data
not shown). Once again, RUNX1-MTG8, but not a mutant
that fails to bind to DNA (L148D) or a mutant that lacks key
corepressor recruitment domains (⌬469), repressed NF1 (Fig.
4E and F). Although the inactive mutants of RUNX1-MTG8
were expressed at high levels, the wild-type protein was expressed at levels comparable to those found in Kasumi-1 cells
(Fig. 4F). Thus, NF1 can be repressed by RUNX1-MTG8.
RUNX1-MTG8 expression phenocopies loss of Nf1 for
growth of myeloid cells induced by GM-CSF. Although the
NF1 promoter is not highly conserved between humans and
mice, the murine promoter contains four perfect RUNX1
binding sites, two of which are clustered similar to the a and b
sites shown in Fig. 3. Therefore, we tested the effects of
RUNX1-MTG8 on the expression of Nf1 in primary myeloid
progenitor cells. For comparison, we isolated myeloid progenitor cells from embryonic day 13.5 livers of mice derived from
breeding Nf1⫹/⫺ mice, which yielded wild-type, Nf1⫹/⫺, and
Nf1⫺/⫺ embryos (fetal liver cells were used due to the midgestation lethality observed in Nf1⫺/⫺ embryos) (7, 28). Fetal
liver hematopoietic progenitor cells of each genotype were
infected with RUNX1-MTG8-expressing retroviruses, and repression of Nf1 in the GPF-expressing population was observed using immunoblot analysis after FACS-based cell sorting (Fig. 5A).
One of the effects of loss of NF1 is to stimulate RASdependent signaling due to the loss of negative regulation (5,
12). However, these effects are small and difficult to measure
accurately. Nevertheless, these small changes in RAS-GTP
levels have dramatic effects on signaling (25, 27, 36). A more
robust assay for the loss of NF1 function is the observation that
loss of NF1 sensitizes myeloid progenitor cells to the growthpromoting effects of GM-CSF, but not IL-3 (5, 15, 35). When
equal numbers of infected progenitor cells were cultured in
methylcellulose containing IL-3, a similar number of colonies
were observed in all genotypes in the presence or absence of

HEL cells, which express RUNX1, but not RUNX1-MTG8. The antibodies used were the same as those described for panel B. (D) SYBR
green fluorescence curves from quantitative PCR from a representative experiment using Kasumi-1 cells and the a set of primers. The
lower part shows amplification of the p16ink4a promoter as a control.
RFU, relative fluorescence units.

Downloaded from http://mcb.asm.org/ on January 6, 2014 by Washington University in St. Louis

FIG. 3. RUNX1 and RUNX1-MTG8 associate with the endogenous NF1 promoter. (A) Schematic diagram of the NF1 promoter
showing the locations of the a and b sets of PCR primers (arrows) used
in the ChIP analysis. The ethidium bromide-stained gel above the
diagram shows a representative analysis of the sheared genomic DNA.
(B) ChIP analysis of the NF1 promoter. The antibodies (Ab) used are
as indicated above each lane. ␣-N-RUNX1, antibody to the N terminus
of RUNX1; RHD-RUNX1, a second anti-RUNX1 directed to the
DNA binding domain; ␣-ZnF-MTG8, anti-ETO Ab-1. The a primers
were used for the analysis shown in the upper part and the b primers
for the middle part. The lower part shows amplification of p16ink4a as
a control for experiment b, but similar results were obtained for part a
using quantitative PCR. (C) ChIP analysis of the NF1 promoter from
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the fusion protein, indicating that RUNX1-MTG8 had little or
no effect on the growth of myeloid progenitor cells cultured in
IL-3 (Fig. 5B). However, when cultured in methylcellulose
containing GM-CSF, RUNX1-MTG8 expression dramatically
increased the number of colonies formed in all but the highest
levels of GM-CSF (Fig. 5C). In fact, the RUNX1-MTG8-expressing cells in a wild-type or heterozygous Nf1 background
grew similarly to Nf1-null cells (Fig. 5C). However, RUNX1MTG8 did not further enhance the number of colonies formed
when both alleles of NF1 were deleted (Fig. 5C, RUNX1MTG8/NF1⫺/⫺), suggesting that the RUNX1-MTG8-mediated enhancement of growth was due to the repression of NF1
and was not due to a general enhancement of proliferation.
NF1 mRNA is underrepresented in M2 AML. Patients with
NF1 mutations are at increased risk for the formation of
JMML, but mutations in NF1 have not been reported in spo-

radic AML. Therefore, we defined the levels of expression of
NF1 in AML patient samples to determine whether NF1 is
regulated epigenetically. We used QRT-PCR to measure NF1
mRNA levels in AML (Fig. 6A). NF1 was differentially expressed over a range of nearly 3 logs. Given that hematopoietic
cells containing only one allele of Nf1 display sensitivity to
cytokines, this finding suggests that NF1 levels may be affected
in many forms of AML. Nevertheless, we noted that the median levels of NF1 mRNA in FAB M2 AML [with and without
t(8;21)] were lower than the median of the other AML samples
(Fig. 6A; 95% confidence interval, 0.073 to 0.365; P value of
0.0071). Because t(8;21) is frequently present in M2 AML, we
further subdivided M2 leukemia to compare AML samples
with and without t(8;21). Compared to the other subtypes of
AML, NF1 mRNA levels were about 50% lower in the AML
M2 samples without t(8;21) (Fig. 6A; 95% confidence interval,
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FIG. 4. NF1 encodes long-lived mRNA and protein. (A) NF1 is a stable protein in HeLa cells. HeLa cells were treated with cycloheximide to
block protein synthesis, and NF1 protein levels were determined by immunoblot analysis at the times indicated above the lanes. GAPDH and c-Myc
were used as controls (Con) for a stable and an unstable protein, respectively. (B) NF1 mRNA has a prolonged t1/2. COS7-L and HeLa cells were
treated with actinomycin D to block transcription, and mRNA extracted for RNA blot analysis at the times indicated above the lanes. GAPDH
and c-Myc were used as controls. (C and D) RUNX1-MTG8 represses endogenous NF1. In panel C, cells infected as described for panel A were
used for RNA blot analysis to detect the indicated mRNAs at 3, 5, and 8 days postinfection. The bottom part shows the same blot probed with
GADPH as a loading control. In panel D, HeLa cells were infected with recombinant retroviruses expressing CBF␤-IRES-GFP and then reinfected
with retroviruses expressing RUNX1-MTG8-IRES-puromycin resistance. Immunoblot analysis was used to detect the indicated proteins at 0, 3,
5, and 8 days postinfection. Duplicate samples of cells expressing only CBF␤ or the puromycin resistance-encoding empty vector (Vector) and
selected in puromycin for 5 days are shown as controls. (E and F) RUNX1-MTG8 represses NF1 in COS7-L cells. COS7-L cells were transfected
with the indicated plasmids, and the levels of the indicated proteins were determined by immunoblotting 5 days later (the cells were split once at
day 3). R/M, RUNX1-MTG8; CMV, cytomegalovirus.
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DISCUSSION

FIG. 5. RUNX1-MTG8-expressing cells are hypersensitive to GMCSF. (A) RUNX1-MTG8 represses Nf1 in murine myeloid progenitor
cells. Murine myeloid progenitor cells were isolated from the fetal livers of
day 13.5 embryos derived from a cross of Nf1⫹/⫺ mice, which allowed the
isolation of cells that contained both alleles (Nf1⫹/⫹) or one allele
(Nf1⫹/⫺) or lacked Nf1 (Nf1⫺/⫺). These cells were then infected with
recombinant retroviruses expressing GFP or RUNX1-MTG8-IRES-GFP.
GFP⫹ c-Kit⫹ double-positive cells were isolated by FACS and expanded
in vitro, and the levels of Nf1 protein were determined by immunoblot
analysis. (B and C) RUNX1-MTG8 stimulates colony formation in response to GM-CSF. RUNX1-MTG8-expressing fetal liver progenitor
cells were identified by FACS and plated in methylcellulose containing
IL-3 (B) or GM-CSF (C). The number of colonies growing in IL-3 (B) or
GM-CSF (C) was plotted as a function of the cytokine concentration. A
representative experiment, performed in triplicate, is shown. ⫹/⫹, ⫾, and
⫺/⫺ denote Nf1 wild-type, heterozygous, and null genotypes, respectively.
R/M, RUNX1-MTG8; GFP, MSCV-IRES-GFP vector control.

⫺0.0539 to 0.4321; P value of 0.0994) and fourfold lower in the
samples containing t(8;21), although one sample appeared to
have aberrantly high levels of NF1 mRNA [Fig. 6A; 95% confidence interval for t(8;21) versus other AML, 0.047 to 0.414; P
value of 0.0169].

Mutations in NF1 represent a common familial cancer syndrome, but de novo mutations of NF1 in leukemia are rare (29,
42, 55, 56). We have established that NF1 is a direct transcriptional target of RUNX1 and the t(8;21) fusion protein. Given
that t(8;21) is the most frequent chromosomal translocation in
AML (58), our results suggest that regulation of NF1 is a
frequent event in AML. In addition, RUNX1 is inactivated by
point mutations in M0 AML, and RUNX1-dependent gene
regulation is disrupted directly or indirectly by other chromosomal translocations in myeloid and B-cell acute leukemia
(43). Therefore, up to 20% of acute leukemias may show
misregulation of NF1 expression through disruption of
RUNX1 function alone. In addition, C/EBP␣ cooperated with
RUNX1 to activate NF1 (Fig. 1), implying that this factor may
also regulate NF1. Although we did not focus on C/EBP␣,
mutations in CEBP〈 are associated with the M2 subgroup of
AML (49, 53). Thus, NF1 may also be misregulated in these
cases. Because phenotypes such as sensitivity to GM-CSF are
associated with haploinsufficiency of NF1 (35), even a modest
reduction in the levels of NF1 should stimulate proliferation
and survival (3, 26) and cooperate with secondary mutations.
In this regard, it is notable that c-KIT, but not other tyrosine
kinase receptors, is mutated at high frequency in t(8;21)-containing AML, and NF1 modulates signals emanating from cKIT (4, 26, 33, 62).
In addition to NF1, the p14ARF tumor suppressor is also
repressed by RUNX1-MTG8 (Fig. 4) (39). p14ARF is induced
by oncogenic activation such as overexpression of c-Myc or
mutational activation of RAS (14). Once induced, p14ARF
binds to and inactivates MDM2, which stabilizes the p53 tumor
suppressor, to trigger growth arrest or apoptosis. In addition,
p14ARF has p53-independent activity in growth inhibition (63).
Loss of p19ARF expression and loss of NF1 expression cooperate to induce multiple tumor types (32). The repression of NF1
and p14ARF suggests a model for how RUNX1-MTG8 may set
the stage for the development of leukemia. The repression of
NF1 may stimulate RAS activity or sensitize the cells to pro-
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Although the levels of NF1 mRNA appeared to be lower in
patient samples containing t(8;21) (Fig. 6A), the variability of
NF1 expression across various subtypes of AML complicates
the interpretation. Therefore, we sought to confirm that
RUNX1-MTG8 was associated with the NF1 promoter in t(8;
21)-containing leukemic blasts. We obtained a fresh bone marrow aspirate from a patient who had relapsed t(8;21)-containing AML with a relatively high blast count (66%). Proteins
were cross-linked to DNA using formaldehyde and subjected
to ChIP analysis using anti-N-terminal RUNX1 coupled with
QRT-PCR (Fig. 6B, upper part). In addition, we were able to
obtain several vials of marrow from this same patient which
had only been frozen for a few days and that retained very high
viability (⬎90%) to perform a second round of ChIP using
anti-ZnF-MTG8 (anti-ETO Ab-1, Fig. 6B, middle part). Both
anti-N-RUNX1 and anti-ZnF-MTG8 yielded a positive signal
compared to an irrelevant control antibody or to the p16ink4a
promoter (Fig. 6B, bottom part and data not shown), which
places RUNX1-MTG8 at the endogenous NF1 promoter in
leukemic blasts.
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liferation in response to cytokines (e.g., GM-CSF; Fig. 5),
while the repression of p14ARF inactivates the oncogene checkpoint to allow unchecked growth. If this is so, it would provide
hematopoietic stem cells and myeloid progenitors harboring
t(8;21) a selective advantage, perhaps by increasing their survival, and allow further oncogenic mutations to arise.
The targeting of NF1 and p14ARF by the t(8;21) fusion protein has a corollary in solid tumors as deletion of 9p22, encompassing the p14ARF/p16ink4A locus, is associated with progression to malignancy in neurofibromatosis type I patients
(50). One distinction in this case is that the 9p22 deletion also
removes the p16ink4A tumor suppressor. While p16ink4A did not
appear to be a direct target for repression by RUNX1-MTG8,
silencing of p16ink4A may be one of the secondary events that
cooperate with repression of NF1 and p14ARF in leukemogenesis because p16ink4A mRNA levels were also very low in t(8;
21)-containing leukemic blasts (39). Nevertheless, in gene ablation studies with mice, inactivation of only p19ARF (the
murine homologue of p14ARF) cooperated with loss of NF1 in
tumorigenesis (32). Moreover, when only one allele of each
tumor suppressor was deleted, a situation that may be more
analogous to repression, the latency of tumor formation was
shortened (32). Thus, repression of NF1 and p14ARF would be
anticipated to cooperate with other mutations, including epigenetic regulation of p16ink4A or oncogenic activation of tyrosine kinases such as c-KIT, in leukemogenesis.
The analysis of the expression of a given gene in AML
samples is extremely difficult because only the endpoint (transformed cells) can be used without the appropriate normal
control cell that would match the leukemic blast. This is further
complicated by differences in the genetic backgrounds of the
individuals, which can greatly affect the basal transcription of
genes (9, 48, 51). When these differences are coupled with
secondary mutations, and the varied AML subtypes with distinct phenotypes and blocks of differentiation, it is extremely
difficult to interpret subtle differences in gene expression. Our
cohort of 49 AML samples contained an unusually high number of AML M2 (Fig. 6), which aided our analysis of this
subgroup. Even so, the differences in NF1 mRNA levels were
not as distinct as those observed previously for p14ARF or
CEBPA (39, 52). Given the multitude of data indicating that
NF1 is a direct transcriptional target of RUNX1-MTG8 (Fig. 3
to 6), including detecting the fusion protein bound to the NF1
promoter in leukemic blasts, this may simply indicate that NF1
is a more widespread target for gene silencing in AML, thereby
making repression by RUNX1-MTG8 less evident. Nevertheless, in our cohort the results were significant at the 95%
confidence level.
The observation that RUNX1-MTG8 represses NF1 and
stimulates the growth of isogenic myeloid progenitor cells isolated from inbred mouse strains in response to GM-CSF (Fig.
5) may also have therapeutic implications. Our results suggest
that t(8;21)-containing leukemic blasts may be hyperproliferative in response to GM-CSF or SCF and therefore sensitive to

legend to Fig. 3. The a primers (Fig. 3A) were used for the analysis
shown. The lower part shows amplification of the p16ink4a promoter as
a control. RFU, relative fluorescence units.
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FIG. 6. Levels of NF1 mRNA in AML samples. NF1 mRNA levels
in 49 AML patient samples were determined using QRT-PCR and
normalized using the porphobilinogen deaminase gene (PBGD) as an
internal control for the amount of mRNA added to each reaction
mixture. The level of NF1 mRNA in each sample was plotted on a
logarithmic scale. The median is indicated with a solid bar with the
value shown beside it. The samples were subdivided into non-M2
AML, FAB M2 without t(8;21), and t(8;21)-containing samples.
(B) ChIP analysis of the NF1 promoter from a t(8;21)-containing
patient sample. The antibodies used are described in more detail in the
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